$878 Million is the total value of JOHNSON & JOHNSON's 24 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals, Inc. | $216,196,000 | +6.2% | 3,260,869 | 0.0% | 24.61% | +37.8% | |
| FATE | Fate Therapeutics, Inc. | $197,709,000 | -1.3% | 3,379,064 | 0.0% | 22.51% | +28.1% | |
| PTGX | Protagonist Therapeutics Inc. | $83,762,000 | +93.0% | 2,449,183 | 0.0% | 9.54% | +150.5% | |
| LEGN | Legend Biotech Corporationads | $75,936,000 | -7.8% | 1,629,173 | 0.0% | 8.64% | +19.6% | |
| Cue Health, Inc. | $74,410,000 | +13.5% | 5,548,864 | 0.0% | 8.47% | +47.3% | ||
| MGTX | MeiraGTx Holdings plc | $68,812,000 | +80.1% | 2,898,550 | 0.0% | 7.83% | +133.8% | |
| CVRX | CVRx, Inc. | $42,751,000 | -26.1% | 3,495,575 | 0.0% | 4.87% | -4.0% | |
| XNCR | New | Xencor, Inc. | $30,012,000 | – | 748,062 | +100.0% | 3.42% | – |
| Procept BioRobotics Corporation | $25,472,000 | -34.4% | 1,018,478 | 0.0% | 2.90% | -14.9% | ||
| FUSN | Fusion Pharmaceuticals Inc. | $15,306,000 | -47.3% | 3,670,516 | 0.0% | 1.74% | -31.7% | |
| ACET | Adicet Bio, Inc. | $12,749,000 | +123.1% | 728,944 | 0.0% | 1.45% | +189.6% | |
| VOR | Vor Biopharma, Inc. | $12,488,000 | -25.9% | 1,074,658 | 0.0% | 1.42% | -3.8% | |
| PNT | Point Biopharma Global Inc. | $5,600,000 | -27.2% | 1,000,000 | 0.0% | 0.64% | -5.5% | |
| PHAS | PhaseBio Pharmaceuticals, Inc. | $4,194,000 | -16.1% | 1,607,044 | 0.0% | 0.48% | +8.9% | |
| PHGE | BiomX Inc. | $3,413,000 | -47.7% | 2,133,402 | 0.0% | 0.39% | -32.1% | |
| SomaLogic, Inc. | $3,271,000 | -6.1% | 281,052 | 0.0% | 0.37% | +22.0% | ||
| NNOX | New | Nano-X Imaging Ltd. | $2,798,000 | – | 192,429 | +100.0% | 0.32% | – |
| ALDX | Aldeyra Therapeutics, Inc. | $1,579,000 | -54.5% | 394,834 | 0.0% | 0.18% | -40.8% | |
| CSLT | Castlight Health, Inc. | $1,249,000 | -2.0% | 811,295 | 0.0% | 0.14% | +26.8% | |
| TCON | Tracon Pharmaceuticals, Inc. | $233,000 | -28.3% | 84,003 | 0.0% | 0.03% | -6.9% | |
| LUNG | Pulmonx Corporation | $181,000 | -10.8% | 5,639 | 0.0% | 0.02% | +16.7% | |
| SENS | Senseonics Holdings, Inc. | $146,000 | -21.1% | 54,621 | 0.0% | 0.02% | +6.2% | |
| GRAY | Graybug Vision, Inc. | $91,000 | -44.5% | 49,547 | 0.0% | 0.01% | -28.6% | |
| CBIO | Catalyst Biosciences, Inc. | $61,000 | -77.8% | 66,951 | 0.0% | 0.01% | -70.8% | |
| ZY | Exit | ZYMERGEN INC. | $0 | – | -16,553 | -100.0% | -0.02% | – |
| NPCE | Exit | NEUROPACE, INC. | $0 | – | -55,435 | -100.0% | -0.08% | – |
| ILMN | Exit | ILLUMINA, INC. | $0 | – | -810,170 | -100.0% | -28.83% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.